Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Realistic timelines support long-term success
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction
16.6% average body weight loss Adults taking Wegovy 25mg tablets lost an average of 16.6% body weight over 64 weeks with full adherence, alongside diet and physical activity
Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone
US$ 25.94
US$ 20.88
US$ 24.28
US$ 25.50
